Bioinformatics Market Size, Share, Opportunities, And Trends By Application (Drug Discovery, Personal and Preventive Medicine, Crop Improvement and Insect Resistance, Others), By Biological Data (DNA, RNA, Protein, Gene Expression Profiles, Chromosomal Mapping, Others), And By Geography - Forecasts From 2025 To 2030

The bioinformatics market is projected to grow at a CAGR of 15.48% during the forecast period.

Bioinformatics is the use of computational and analytical tools to gather and analyze biological data. The use of computer programs to discover gene and protein functions, establish evolutionary connections, and forecast the three-dimensional structures of proteins is known as bioinformatics.

Bioinformatics is becoming crucial since massive volumes of data generated by techniques such as protein and nucleic acid sequencing necessitate data interpretation and management for medical applications and future research. As a result, growing demand is projected to propel the bioinformatics market throughout the forecast period.

However, expensive bioinformatics software and service prices, as well as a scarcity of experienced specialists, are anticipated to impede industry expansion in the coming years.

Growth Factor

• Increasing bioinformatics funding from the public and private sectors.

Many governments and private companies across the globe are making substantial investments in bioinformatics to enable high-quality solutions and services through data and the latest technologies. For instance, with a EUR 20 million investment, the UK government formed a new alliance named COVID-19 Genomics UK Consortium (COG-UK) in March 2020 to sequence the genomes of SARS-CoV-2 the virus that is causing the ongoing COVID-19 pandemic. The NHS, Public Health Agencies, the Wellcome Sanger Institute, and several academic institutions comprise the COVID-19 Genomics UK Consortium (COG-UK). Such factors are anticipated to drive the growth of the bioinformatics market.

Restraints

• High Equipment Costs

With the introduction of sophisticated next-generation sequencing (NGS) technology, there is a growing demand for rapid and accurate bioinformatics tools that are simple to use. The majority of experimental researchers are not bioinformaticians. As a result, the availability of user-friendly tools is critical for using bioinformatics platforms. Many bioinformatics applications necessitate extensive computer skills, owing to a lack of a suitable user interface. Genomics instruments are also outfitted with advanced features and functions, and as a result, they are priced at a premium, ranging from USD 10–20 million. Since pharmaceutical companies and research institutes require a large number of such devices, the financial investment in acquiring many genomic instruments is substantial. Small and medium-sized pharmaceutical companies and research facilities cannot afford to make such large expenditures in numerous genomics equipment.

Impact of Covid-19 pandemic

The COVID-19 is anticipated to have a negative influence on bioinformatics market growth since the pandemic affected supply chains and industrial operations all across the world. As a result, manufacturing capacity and bioinformatics supply will be reduced, which is likely to stifle market growth.

Competitive Insight:

• January 2021 - The Pan-Cancer IVD Test, Cloud-Based Bioinformatics Platform was launched by Illumina.
• April 2020 - Strand Life Sciences and Healthcare Global Enterprises launched the StrandAdvantage500, a Next-Generation Sequencing (NGS)-based assay that evaluates cancer-relevant genetic changes using DNA and RNA obtained from a patient's tumor in a single integrated workflow.

Market Segmentation:

• By Application
  • Drug Discovery
  • Personal and Preventive Medicine
  • Crop Improvement and Insect Resistance
  • Others
• By Biological data
  • Genomics
  • Pharmacogenomics
  • Cheminformatic
  • Proteomics
  • Others
• By Geography 
  • North America 
    • United States
    • Canada
    • Mexico
  • South America 
    • Brazil
    • Argentina
    • Others
  • Europe 
    • UK
    • Germany
    • Italy
    • Spain
    • Others
  • Middle East and Africa 
    • Israel
    • Saudi Arabia
    • Others
  • Asia Pacific 
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Covid-19 Scenario

1.3. Market Definition

1.3. Scope of the Study

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Secondary Sources

2.3. Validation

3. KEY FINDINGS

4. MARKET DYNAMICS

4.1. Segmentation

4.2. Drivers

4.2.1. Increasing Investments in Bioinformatics

4.2.2. Growing Demand for Next Generation Sequencing and Drug Discovery Informatics

4.3. Restraints

4.3.1. High Equipment Cost

4.4. Porter’s Five Forces Analysis

4.4.1. Bargaining Power of Suppliers

4.4.2. Bargaining Power of Buyers

4.4.3. Threat of New Entrants

4.4.4. Threat of Substitutes

4.4.5. Competitive Rivalry in the Industry

4.5. Industry Value Chain Analysis

5. BIOINFORMATICS MARKET BY APPLICATION

5.1. Introduction

5.2. Drug Discovery

5.3. Personal & Preventive Medicine

5.4. Crop Improvement & Insect Resistance

5.5. Others

6. BIOINFORMATICS MARKET BY BIOLOGICAL DATA

6.1. Introduction

6.2. Genomics

6.3. Pharmacogenomics

6.4. Cheminformatic

6.5. Proteomics

6.6 Others

7. BIOINFORMATICS MARKET BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. USA

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. United Kingdom

7.4.2. Germany

7.4.3. Italy

7.4.4. Spain

7.4.5. Others

7.5. Middle East And Africa

7.5.1. Israel

7.5.2. Saudi Arabia

7.5.3. Others

7.6. Asia Pacific

7.6.1. China

7.6.2. Japan

7.6.3. India

7.6.4. Australia

7.6.5. South Korea

7.6.6. Taiwan

7.6.7. Thailand

7.6.8. Indonesia

7.6.9. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

9.1. PerkinElmer

9.1.1. Overview

9.1.2. Products and Services

9.1.3. Financials

9.1.4. Key Developments

9.2. SciGenom Labs Pvt. Ltd.

9.2.1. Overview

9.2.2. Products and Services

9.2.3. Key Developments

9.3. TeselaGen

9.3.1. Overview

9.3.2. Products and Services

9.3.3. Key Developments

9.4. Era7 Information Technologies

9.4.1. Overview

9.4.2. Products and Services

9.5. Agilent Technologies

9.5.1. Overview

9.5.2. Products and Services

9.5.3. Financials

9.5.4. Key Developments

9.6. Thermo Fisher Scientific

9.6.1. Overview

9.6.2. Products and Services

9.6.3. Financials

9.6.4. Key Developments

9.7. Illumina Inc.

9.7.1. Overview

9.7.2. Products and Services

9.7.3. Financials

9.7.4. Key Developments

9.8. DNAnexus

9.8.1. Overview

9.8.2. Products and Services

9.8.3. Key Developments

9.9. Strand Life Sciences

9.9.1. Overview

9.9.2. Products and Services

9.9.3. Key Developments

9.10. Phalanx Biotech Group

9.10.1. Overview

9.10.2. Products and Services

9.11. Glucore

9.11.1. Overview

9.11.2. Products and Services

9.11.3. Key Developments

9.12. Qiagen NV

9.12.1. Overview

9.12.2. Products and Services

9.12.3. Financials

9.12.4. Key Developments

LIST OF TABLES

LIST OF FIGURES